Detalhe da pesquisa
1.
Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes.
Blood
; 141(17): 2047-2061, 2023 04 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36724453
2.
Patterns of Diagnostic Evaluation and Determinants of Treatment in Older Patients With Non-transfusion Dependent Myelodysplastic Syndromes.
Oncologist
; 28(10): 901-910, 2023 10 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-37120291
3.
Machine learning integrates genomic signatures for subclassification beyond primary and secondary acute myeloid leukemia.
Blood
; 138(19): 1885-1895, 2021 11 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34075412
4.
Roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndrome: Open-label, dose-selection, lead-in stage of a phase 3 study.
Am J Hematol
; 97(2): 174-184, 2022 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34724251
5.
Extended experience with a non-cytotoxic DNMT1-targeting regimen of decitabine to treat myeloid malignancies.
Br J Haematol
; 188(6): 924-929, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31736067
6.
Large granular lymphocytic leukaemia after solid organ and haematopoietic stem cell transplantation.
Br J Haematol
; 189(2): 318-322, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31958160
7.
Distinctive and common features of moderate aplastic anaemia.
Br J Haematol
; 189(5): 967-975, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32004386
8.
Validation of the Molecular International Prognostic Scoring System in patients with myelodysplastic syndromes.
Blood
; 141(14): 1768-1772, 2023 04 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36720101
9.
Novel therapeutic strategies to target leukemic cells that hijack compartmentalized continuous hematopoietic stem cell niches.
Biochim Biophys Acta Rev Cancer
; 1868(1): 183-198, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28363872
10.
Descriptive comparison of hospital formulary decisions with published oncology valuation methods.
J Oncol Pharm Pract
; 26(4): 891-905, 2020 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-31594520
11.
Are we ready to ring in a new upfront therapy in lower-risk myelodysplastic syndromes?
Lancet
; 402(10399): 348-350, 2023 07 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-37321236
12.
Vacuolization of hematopoietic precursors: an enigma with multiple etiologies.
Blood
; 137(26): 3685-3689, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33690844
13.
A phase 2 trial of high dose lenalidomide in patients with relapsed/refractory higher-risk myelodysplastic syndromes and acute myeloid leukaemia with trilineage dysplasia.
Br J Haematol
; 176(2): 241-247, 2017 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-27790720
14.
A phase I/II multicenter, open-label, dose escalation and randomized trial of BI 836858 in patients with low- or intermediate-1-risk myelodysplastic syndrome.
Haematologica
; 107(11): 2742-2747, 2022 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35734924
15.
Molecular features of early onset adult myelodysplastic syndrome.
Haematologica
; 102(6): 1028-1034, 2017 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-28255022
16.
Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients.
Blood
; 124(3): 385-92, 2014 Jul 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-24859366
17.
Genomics of therapy-related myeloid neoplasms.
Haematologica
; 105(3): e98-e101, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31413096
18.
Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia.
Blood
; 119(1): 55-63, 2012 Jan 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-22001391
19.
A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms.
Haematologica
; 99(4): 672-8, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24362550
20.
Overview of the Management of Higher-Risk Myelodysplastic Syndromes.
Cancer J
; 29(3): 160-167, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37195772